Newswire (Published: Friday, August 23, 2019, Received: Friday, August 23, 2019, 5:27:07 PM CDT)

Word Count: 454

2019 AUG 23 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Hannover, Germany, by NewsRx editors, research stated, “Prostate-specific antigen (PSA) based screening for early detection of prostate cancer is common although it is associated with both benefits and potential harms (e.g., the risk of overdiagnosis). Evidence-based health information could help individuals make informed decisions about whether to undergo PSA testing or not.”

Our news journalists obtained a quote from the research from Hannover Medical School, “This evaluation aimed to determine whether the written health information materials available in Germany provide appropriate information for informed decision-making on PSA based screening. A list of criteria was developed and used to systematically assess the quality of information on the benefits and harms of prostate cancer screening included in written health information materials. Fourteen information materials identified by information requests and online searches were evaluated independently by two of three reviewers. Consensus was achieved with a third reviewer. Of the 14 information materials evaluated, 10 (71%) list the ability to reduce the absolute risk of death from prostate cancer as a benefit of PSA testing, 9 (64%) point out the risks of follow-up diagnostics, 13 (93%) describe the risks of the available prostate cancer treatments, and all 14 specify the risk of overdiagnosis. The minority provide numerical data on benefits and risks. Partially mismatched framing was identified in four cases: two information materials report only the relative frequencies of benefits, and two report only the absolute frequencies of harms. Half of the materials encouraged participation using downplaying or frightening language.”

According to the news editors, the research concluded: “The majority of health information materials in Germany describe the benefits and harms of PSA based screening, including overdiagnosis, but often lack adequate balance, neutrality and numbers.”

For more information on this research see: Systematic evaluation of written health information on PSA based screening in Germany. Plos One, 2019;14(8):e0220745. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)

Our news journalists report that additional information may be obtained by contacting S. Beck, Institute of Epidemiology, Social Medicine and Health Systems Research, Hannover School of Medicine, Hannover, Germany. Additional authors for this research include B. Borutta, U. Walter and M. Dreier.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1371/journal.pone.0220745. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Public Library of Science

Industries

Healthcare
      Healthcare Technology
            Medical Information Systems

Places

Western Europe
Germany
Europe
Hannover

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research